Substance use and hepatitis C: An ecological momentary assessment study

Health Psychology

Volumn 33, Issue 7, 2014, Pages 710-719

  Phillips, Karran A ^a   Epstein, David H ^a   Vahabzadeh, Massoud ^a   Mezghanni, Mustapha ^b   Lin, Jia Ling ^a   Preston, Kenzie L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Craving; Ecological momentary assessment; Hepatitis C; Mood; Triggers

Indexed keywords

COCAINE; DIAMORPHINE; METHADONE; OPIATE; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BOREDOM; DRUG EXPOSURE; DRUG USE; EMOTION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MOOD CHANGE; MOOD DISORDER; PATIENT WORRY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; STRESS; SUBSTANCE USE; WITHDRAWAL SYNDROME; AFFECT; COCAINE-RELATED DISORDERS; HEROIN DEPENDENCE; MIDDLE AGED; PSYCHOLOGY;

ADULT; AFFECT; ANTIVIRAL AGENTS; COCAINE-RELATED DISORDERS; CRAVING; FEMALE; HEPATITIS C; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK-TAKING;

EID: 84903554296     PISSN: 02786133     EISSN: 19307810     Source Type: Journal    
DOI: 10.1037/hea0000087     Document Type: Article

References (63)

1. Alexander, J. A., Nahra, T. A., Lemak, C. H., Pollack, H.,&Campbell, C. I. (2008). Tailored treatment in the outpatient substance abuse treatment sector: 1995-2005. Journal of Substance Abuse Treatment, 34, 282-292.
2. American Society of Addiction Medicine. (2001). Patient placement criteria for the treatment of substance related disorders (2nd Rev. ed.). Chevy Chase, MD: Author.
3. Batki, S. L., Canfield, K. M., Smyth, E.,&Ploutz-Snyder, R. (2009). Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. Drug and Alcohol Dependence, 101, 176-182.
4. Bickel, W. K., Jarmolowicz, D. P., Mueller, E. T., Koffarnus, M. N., & Gatchalian, K. M. (2012). Excessive discounting of delayed reinforcers as a trans-disease process contributing to addiction and other diseaserelated vulnerabilities: Emerging evidence. Pharmacology&Therapeutics, 134, 287-297.
5. Bickel, W. K.,&Marsch, L. A. (2001). Toward a behavioral economic understanding of drug dependence: Delay discounting processes. Addiction, 96, 73-86.
6. Chaudhry, A. A., Botsko, M., Weiss, L., Egan, J. E., Mitty, J., Estrada, B.,. . . Fiellin, D. A. (2011). Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. Journal of Acquired Immune Deficiency Syndrome, 56(Suppl. 1), S14-S21.
7. Cooper, C. L.,&Mills, E. J. (2006). Therapeutic challenges in hepatitis C-infected injection drug using patients. Harm Reduction Journal, 3, 31.
8. Crofts, N., Hopper, J. L., Bowden, D. S., Breschkin, A. M., Milner, R., & Locarnini, S. A. (1993). Hepatitis-C virus-infection among a cohort of Victorian injecting drug users. Medical Journal of Australia, 159, 237-241.
9. Crofts, N., Nigro, L., Oman, K., Stevenson, E.,&Sherman, J. (1997). Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction, 92, 999-1005.
10. Dore, G. J.,&Thomas, D. L. (2005). Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Seminars in Liver Disease, 25, 18-32.
11. Drake, R. E., Wallach, M. A.,&McGovern, M. P. (2005). Future directions in preventing relapse to substance abuse among clients with severe mental illnesses. Psychiatric Services, 56, 1297-1302.
12. Dwight, M. M., Kowdley, K. V., Russo, J. E., Ciechanowski, P. S., Larson, A. M.,&Katon, W. J. (2000). Depression, fatigue, and functional disability in patients with chronic hepatitis C. Journal of Psychosomatic Research, 49, 311-317.
13. Epstein, D. H., Marrone, G. F., Heishman, S. J., Schmittner, J.,&Preston, K. L. (2010). Tobacco, cocaine, and heroin: Craving and use during daily life. Addictive Behaviors, 35, 318-324.
14. Epstein, D. H.,&Preston, K. L. (2010). Daily life hour by hour, with and without cocaine: An ecological momentary assessment study. Psychopharmacology, 211, 223-232.
15. Epstein, D. H., Willner-Reid, J., Vahabzadeh, M., Mezghanni, M., Lin, J. L.,&Preston, K. L. (2009). Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Archives of General Psychiatry, 66, 88-94.
16. Erim, Y., Tagay, S., Beckmann, M., Bein, S., Cicinnati, V., Beckebaum, S.,. . . Schlaak, J. F. (2010). Depression and protective factors of mental health in people with hepatitis C: A questionnaire survey. International Journal of Nursing Studies, 47, 342-349.
17. Fabris, P., Tositti, G., Giordani, M. T., Baldo, V., Grasso, A., Pignattari, E.,. . . Floreani, A. (2006). Assessing patients' understanding of hepatitis C virus infection and its impact on their lifestyle. Alimentary Pharmacology & Therapeutics, 23, 1161-1170.
18. Forton, D. M., Taylor-Robinson, S. D.,&Thomas, H. C. (2003). Cerebral dysfunction in chronic hepatitis C infection. Journal of Viral Hepatitis, 10, 81-86.
19. Garfein, R. S., Vlahov, D., Galai, N., Doherty, M. C.,&Nelson, K. E. (1996). Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health, 86, 655-661.
20. Gjestad, R., Franck, J., Lindberg, S.,&Haver, B. (2011). Early treatment for women with alcohol addiction (EWA) reduces mortality: A randomized controlled trial with long-term register follow-up. Alcohol and Alcoholism, 46, 170-176.
21. Golden, J., O'Dwyer, A. M.,&Conroy, R. M. (2005). Depression and anxiety in patients with hepatitis C: Prevalence, detection rates and risk factors. General Hospital Psychiatry, 27, 431-438.
22. Hagan, H., Campbell, J., Thiede, H., Strathdee, S., Ouellet, L., Kapadia, F.,. . . Garfein, R. S. (2006). Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports, 121, 710-719.
23. Heather, N., Stallard, A.,&Tebbutt, J. (1991). Importance of substance cues in relapse among heroin users: Comparison of two methods of investigation. Addictive Behaviors, 16, 41-49.
24. Hoofnagle, J. H. (2002). Course and outcome of hepatitis C. Hepatology, 36(Suppl. 1), S21-S29.
25. Huckans, M., Seelye, A., Woodhouse, J., Parcel, T., Mull, L., Schwartz, D.,. . . Hoffman, W. (2011). Discounting of delayed rewards and executive dysfunction in individuals infected with hepatitis C. Journal of Clinical and Experimental Neuropsychology, 33, 176-186.
26. Institute of Medicine. (1990). Broadening the base of treatment for alcohol problems. Washington, DC: National Academy Press.
27. Institute of Medicine. (2001). Crossing the quality chasm: A new health system for the 21st century. Washington, DC: National Academy Press.
28. Klinkenberg, W. D., Caslyn, R. J., Morse, G. A., Yonker, R. D., McCudden, S., Ketema, F.,&Constantine, N. T. (2003). Prevalence of human immunodeficiency virus, hepatitis B, and hepatitis C among homeless persons with co-occurring severe mental illness and substance use disorders. Comprehensive Psychiatry, 44, 293-302.
29. Marlatt, G.,&Gordon, J. (1985). Relapse prevention: Maintenance strategies in the treatment of addictive behaviors. New York, NY: Guilford Press.
30. McLellan, A. T., Luborsky, L., O'Brien, C. P.,&Woody, G. E. (1980). An improved diagnostic instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous and Mental Diseases, 168, 26-33.
31. Metzger, D. S., Woody, G. E.,&O'Brien, C. P. (2010). Drug treatment as HIV prevention: A research update. Journal of Acquired Immune Deficiency Syndrome, 55(Suppl. 1), S32-S36.
32. Millson, P., Challacombe, L., Villeneuve, P. J., Strike, C. J., Fischer, B., Myers, T., . . . Hopkins, S. (2007). Reduction in injection-related HIV risk after 6 months in a low threshold methadone treatment program. AIDS Education and Prevention, 19, 124-136.
33. Minkoff, K. (2000). An integrated model for the management of cooccurring psychiatric and substance disorders in managed-care systems. Disease Management&Health Outcomes, 8, 251-257.
34. National Institute on Drug Abuse. (1999). Principles of addiction treatment: A research-based guide. Bethesda, MD: National Institutes of Health.
35. Nelligan, J. A., Loftis, J. M., Matthews, A. M., Zucker, B. L., Linke, A. M., & Hauser, P. (2008). Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: Results from a retrospective chart review. Journal of Clinical Psychiatry, 69, 810-816.
36. Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D.,&Degenhardt, L. (2011). Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet, 378, 571-583.
37. Niv, N.,&Hser, Y. I. (2007). Women-only and mixed-gender drug abuse treatment programs: Service needs, utilization and outcomes. Drug and Alcohol Dependence, 87, 194-201.
38. Ompad, D. C., Fuller, C. M., Vlahov, D., Thomas, D.,&Strathdee, S. A. (2002). Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, MD. Clinical Infectious Diseases, 35, 783-788.
39. Orwat, J., Saitz, R., Tompkins, C. P., Cheng, D. M., Dentato, M. P., & Samet, J. H. (2011). Substance abuse treatment utilization among adults living with HIV/AIDS and alcohol or drug problems. Journal of Substance Abuse Treatment, 41, 233-242.
40. Poppele, G.,&Anders, H. (2009). Qualified Withdrawal Treatment in Patients Aged Over 60 Years of Age - Developments, Experiences and Prospects in an Age Specific Motivational Offer. Suchttherapie, 10, 28-31.
41. Preston, K. L., Vahabzadeh, M., Schmittner, J., Lin, J. L., Gorelick, D. A., & Epstein, D. H. (2009). Cocaine craving and use during daily life. Psychopharmacology, 207, 291-301.
42. Quaglio, G. L., Lugoboni, F., Pajusco, B., Sarti, M., Talamini, G., Mezzelani, P.,&Des Jarlais, D. C. (2003). Hepatitis C virus infection: Prevalence, predictor variables and prevention opportunities among drug users in Italy. Journal of Viral Hepatology, 10, 394-400.
43. Robins, L. N., Helzer, J. E., Croughan, J.,&Ratcliff, K. S. (1981). National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Archives of General Psychiatry, 38, 381-389.
44. Rosenberg, S. D., Goodman, L. A., Osher, F. C., Swartz, M. S., Essock, S. M., Butterfield, M. I., . . . Salyers, M. P. (2001). Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. American Journal of Public Health, 91, 31-37.
45. Rosnow, R. L., Rosenthal, R.,&Rubin, D. B. (2000). Contrasts and correlations in effect-size estimation. Psychological Science, 11, 446-453.
46. Russell, J. A. (1980). A circumplex model of affect. Journal of Personality and Social Psychology, 39, 1161-1178.
47. Schreuder, I., van der Sande, M. A., de Wit, M., Bongaerts, M., Boucher, C. A., Croes, E. A.,&van Veen, M. G. (2010). Seroprevalence of HIV, hepatitis B, and hepatitis C among opioid drug users on methadone treatment in the Netherlands. Harm Reduction Journal, 7, 25.
48. Selvey, L. A., Denton, M.,&Plant, A. J. (1997). Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: Factors influencing hepatitis C serostatus. Australian and New Zealand Journal of Public Health, 21, 102-104.
49. Sgorbini, M., O'Brien, L.,&Jackson, D. (2009). Living with hepatitis C and treatment: The personal experiences of patients. Journal of Clinical Nursing, 18, 2282-2291.
50. Shiffman, S., Gwaltney, C. J., Balabanis, M. H., Liu, K. S., Paty, J. A., Kassel, J.D., . . . Gnys, M. (2002). Immediate antecedents of cigarette smoking: An analysis from ecological momentary assessment. Journal of Abnormal Psychology, 111, 531-545.
51. Shiffman, S., Stone, A. A.,&Hufford, M. R. (2008). Ecological momentary assessment. Annual Review of Clinical Psychology, 4, 1-32.
52. Smith, B. D., Jorgensen, C., Zibbell, J. E.,&Beckett, G. A. (2012). Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: A selective update. Clinical Infectious Diseases, 55, S49-S53.
53. Stata Corporation. (2007). StataCorp (Version Release 10.0). College Station, TX: Author.
54. Strader, D. B., Wright, T., Thomas, D.,&Seeff, L. (2004). Diagnosis, management, and treatment of hepatitis. Hepatology, 39, 1147-1171.
55. Swan, D., Long, J., Carr, O., Flanagan, J., Irish, H., Keating, S.,. . . Cullen, W. (2010). Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care and STDs, 24(12), 753-762.
56. Thiede, H., Hagan, H.,&Murrill, C. S. (2000). Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health, 77, 331-345.
57. Thomas, H. C., Lok, A. S. F., Locarnini, S. A.,&Zuckerman, A. J. (Eds.). (2013). Viral hepatitis (fourth ed.). Wiley.
58. Treloar, C.,&Rhodes, T. (2009). The lived experience of hepatitis C and its treatment among injecting drug users: Qualitative synthesis. Qualitative Health Research, 19, 1321-1334.
59. Vahabzadeh, M., Epstein, D. H., Mezghanni, M., Lin, J.-L.,&Preston, K. L. (2004). An electronic diary software for ecological momentary assessment (EMA) in clinical trials (pp. 167-172). In Proceedings of the 17th IEEE Symposium on Computer-Based Medical Systems (CBMS).
60. Vahabzadeh, M., Lin, J. L., Mezghanni, M., Epstein, D. H.,&Preston, K. L. (2009). Automation in an addiction treatment research clinic: Computerised contingency management, ecological momentary assessment and a protocol workflow system. Drug and Alcohol Review, 28, 3-11.
61. Vidal-Trécan, G., Coste, J., Varescon-Pousson, I., Christoforov, B., & Boissonnas, A. (2000). HCV status knowledge and risk behaviours amongst intravenous drug users. European Journal of Epidemiology, 16, 439-445.
62. Weinberg, N. Z., Rahdert, E., Colliver, J. D.,&Glantz, M. D. (1998). Adolescent substance abuse: A review of the past 10 years. Journal of the American Academy of Child&Adolescent Psychiatry, 37, 252-261.
63. Willner-Reid, J., Belendiuk, K. A., Epstein, D. H., Schmittner, J., & Preston, K. L. (2008). Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. Journal of Substance Abuse Treatment, 35, 78-86.